Incyte Corporation (NASDAQ:INCY) – Equities researchers at Gabelli cut their FY2020 earnings per share estimates for shares of Incyte Corporation in a report issued on Monday. Gabelli analyst J. He now expects that the biopharmaceutical company will earn $4.20 per share for the year, down from their prior estimate of $4.25. Gabelli has a “Buy” rating and a $174.00 price target on the stock. Gabelli also issued estimates for Incyte Corporation’s FY2021 earnings at $5.20 EPS.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm had revenue of $326.40 million for the quarter, compared to analyst estimates of $318.45 million. During the same quarter last year, the firm earned $0.18 earnings per share. The company’s revenue was up 32.5% compared to the same quarter last year.

TRADEMARK VIOLATION WARNING: “FY2020 Earnings Estimate for Incyte Corporation Issued By Gabelli (INCY)” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/15/fy2020-earnings-estimate-for-incyte-corporation-issued-by-gabelli-incy.html.

INCY has been the topic of several other reports. Oppenheimer Holdings, Inc. set a $125.00 price objective on shares of Incyte Corporation and gave the company a “hold” rating in a research report on Thursday, May 18th. BMO Capital Markets reiterated an “outperform” rating and issued a $163.00 price objective (down from $172.00) on shares of Incyte Corporation in a research report on Monday. Jefferies Group LLC reiterated a “buy” rating and issued a $148.00 price objective on shares of Incyte Corporation in a research report on Thursday, July 27th. J P Morgan Chase & Co set a $149.00 price objective on shares of Incyte Corporation and gave the company a “buy” rating in a research report on Thursday, May 18th. Finally, Credit Suisse Group set a $152.00 price objective on shares of Incyte Corporation and gave the company a “buy” rating in a research report on Sunday, July 16th. Eight investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Incyte Corporation presently has an average rating of “Buy” and a consensus target price of $142.16.

Shares of Incyte Corporation (INCY) traded down 0.51% on Wednesday, hitting $119.15. 2,991,799 shares of the stock were exchanged. Incyte Corporation has a one year low of $79.75 and a one year high of $153.15. The firm’s market cap is $24.51 billion. The firm’s 50 day moving average price is $127.79 and its 200 day moving average price is $130.32.

In other news, insider David W. Gryska sold 599 shares of Incyte Corporation stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $129.74, for a total value of $77,714.26. Following the transaction, the insider now directly owns 19,614 shares of the company’s stock, valued at $2,544,720.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 100,000 shares of the company’s stock in a transaction dated Friday, September 8th. The stock was purchased at an average cost of $132.00 per share, for a total transaction of $13,200,000.00. The disclosure for this purchase can be found here. Insiders sold a total of 53,538 shares of company stock worth $7,118,269 in the last ninety days. Corporate insiders own 17.70% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in INCY. State Street Corp increased its position in shares of Incyte Corporation by 110.7% in the first quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock worth $1,013,437,000 after acquiring an additional 3,983,207 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Incyte Corporation by 22.7% in the first quarter. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company’s stock worth $2,060,638,000 after acquiring an additional 2,847,907 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Incyte Corporation by 4,570.1% in the second quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock worth $131,622,000 after acquiring an additional 1,022,979 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of Incyte Corporation in the first quarter worth approximately $85,751,000. Finally, Geode Capital Management LLC increased its position in shares of Incyte Corporation by 42.0% in the first quarter. Geode Capital Management LLC now owns 1,780,064 shares of the biopharmaceutical company’s stock worth $237,618,000 after acquiring an additional 526,163 shares in the last quarter. 91.06% of the stock is currently owned by institutional investors and hedge funds.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History and Estimates for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.